HUTCHMED (China) Ltd Files Routine 6-K Report
Ticker: HMDCF · Form: 6-K · Filed: Jul 5, 2024 · CIK: 1648257
Sentiment: neutral
Topics: disclosure, sec-filing, foreign-private-issuer
TL;DR
HUTCHMED filed a 6-K, standard disclosure for foreign companies. No major news.
AI Summary
HUTCHMED (China) Limited filed a Form 6-K on July 5, 2024, reporting its status as a foreign private issuer. The filing does not contain specific financial updates or operational news but serves as a routine disclosure.
Why It Matters
This filing indicates HUTCHMED is meeting its ongoing disclosure obligations as a foreign private issuer with the SEC, maintaining transparency for investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- HUTCHMED (China) Limited (company) — Filer of the 6-K report
- 20240705 (date) — Date of the report filing
- 001-37710 (other) — SEC Commission File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.
What is the filing date of this specific 6-K report?
The filing date of this 6-K report is July 5, 2024.
What is the Commission File Number for HUTCHMED (China) Limited?
The Commission File Number for HUTCHMED (China) Limited is 001-37710.
Does this filing indicate any new financial results or operational updates?
No, this filing is a routine report of a foreign private issuer and does not contain specific financial results or operational updates.
What is the principal executive office address for HUTCHMED (China) Limited?
The principal executive office address is 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
Filing Stats: 175 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2024-07-05 06:13:58
Filing Documents
- hcm-20240705x6k.htm (6-K) — 19KB
- hcm-20240705xex99d1.htm (EX-99.1) — 29KB
- hcm-20240705xex99d1001.gif (GRAPHIC) — 4KB
- 0001648257-24-000063.txt ( ) — 55KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant's name into English) 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 Press release relating to NDA acceptance in China for tazemetostat for the treatment of relapsed or refractory follicular lymphoma with priority review status 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HUTCHMED (CHINA) LIMITED By: /s/ Johnny Cheng Name: Johnny Cheng Title: Chief Financial Officer Date: July 5, 2024 3